



European Cystic Fibrosis Registry Report 2006 data

This report contains data collected from existing national registries and from three single centers in Europe. All known national registries were contacted and asked for their co-operation. In case of a positive response, data were collected by a common spreadsheet with core demographic and clinical data, and definitions for the variables. The same spreadsheet was sent to countries all over Europe via the project EuroCareCF WP 2 (Registry) to collect primarily demographic data. The demographic data from countries participating in the EuroCareCF project will be presented elsewhere, whereas this report only presents data from the existing registries and the three centers aforementioned.

The data were extracted from the local databases into the spreadsheet by the national registry and centers representatives. If the fields of the local databases were not compatible with ECFR definitions, they were omitted; others fields were redefined for the transfer after communication with the ECFR.

All data were transferred anonymously (gender, month/year of birth and country) according to the regulations of the Danish Data Protection agency, where the ECFR is registered. Data analysis was performed by the Istituto di Statistica Medica e Biometria "GA Maccacaro" at the University of Milan, Italy.

These data were collected in 2008, and were first presented at the 31st European Cystic Fibrosis Conference in Prague, Czech Republic.

The data have been analyzed according to the European CF Registry Definition Consensus group:

1. we used common reference values for calculation of FEV1% of predicted. We planned to compute z-scores for weight, height and BMI using national reference materials; however only few countries could supply national references, therefore we used international references.
2. All other variables have been recorded using a common set of definitions. Lack of data from some countries on certain variables is attributable to lack of registration in the local database, or to discrepancies between local and ECFR definitions.

We would like to thank the participating countries for their patience and cooperation. Special thanks to the people involved in the data extraction and evaluation of final report:

Linda Foley, Ireland
Herwig Jansen, Belgium
Meir Mei-zahav, Israel
Paul Wenzlaff, Germany
Helmuth Ellemunter, Austria
Ondrej Cinek, Czech Republic
Anders Lindblad, Sweden
Baroukh Maurice Assael, Italy
Lydie Lemonnier, France

November 19th 2009

Hanne Vebert Olesen
European CF Registry Steering
Committee, Denmark

Anna Zolin
Istituto di Statistica Medica e
Biometria "GA Maccacaro", Italy


Laura Viviani
Istituto di Statistica Medica e
Biometria "GA Maccacaro", Italy

This report was supported by unrestricted grants from Roche and IERFC
(European Institute for Research in Cystic Fibrosis)

Table 1 Number of patients reported by each country

country		n
Austria	(A)	107
Belgium	(B)	1036
Czech Republic	(CZ)	457
Denmark	(DK)	438
France	(F)	4994
Germany	(D)	4894
Ireland	(IRL)	832
Israel	(IL)	447
Italy	(I)	771
Sweden	(S)	125
<i>total</i>		<i>14101</i>

Figure 1 Number of patients reported by each country




Data from Italy, Austria and Sweden refer to one centre only.

Table 2 Age (in years) on 31-12-2006

country	mean	min	25 th pctl	median	75 th pctl	max	% adults (≥18 years)
A	16.36	0.46	7.55	14.80	21.80	52.46	42.06
B	18.85	0.21	8.87	17.46	26.38	61.04	47.97
CZ	15.97	0.21	8.46	14.46	21.92	52.54	36.98
DK	21.02	0.71	11.38	18.88	30.21	58.29	52.28
D	18.54	0.15	9.62	16.98	25.61	68.47	46.61
F	16.83	0.04	7.21	15.38	23.80	76.63	40.47
IRL	17.48	0.35	9.34	17.08	23.68	54.52	47.00
IL	19.01	0.04	10.21	17.04	25.63	61.46	46.76
I	21.79	0.16	11.75	20.90	31.52	68.45	56.94
S	21.40	1.54	12.54	19.38	27.96	64.54	56.00
<i>pooled</i>	<i>18.09</i>	<i>0.04</i>	<i>8.83</i>	<i>16.59</i>	<i>25.29</i>	<i>76.63</i>	<i>45.04</i>

Figure 2 Boxplot of age (in years) on 31-12-2006



Boxplots: cross represents median, box represents 25th to 75th percentiles, whiskers represent minimum and maximum.

Figure 3 Gender distribution (pink=females, light blue=males)





Table 3 Age (in years) at diagnosis (*prenatal diagnosis)


country	mean	min	25 th pctl	median	75 th pctl	max	% adults (≥18 years)	% infants (<1 year)
A	2.95	-0.13*	0.10	0.19	0.78	52.81	5.61	68.22
B	4.37	-0.02*	0.15	0.66	3.46	60.05	7.14	54.25
CZ	2.48	at birth	0.21	0.58	2.71	46.92	1.31	56.24
DK	2.19	at birth	0.17	0.50	2.00	70.00	0.91	60.05
D	2.96	at birth	0.18	0.66	2.83	57.55	3.15	53.33
F	3.33	at birth	0.10	0.30	2.30	74.80	4.55	56.55
IRL	2.23	at birth	0.08	0.31	1.68	48.14	2.52	68.03
IL	4.65	at birth	0.08	0.46	4.17	57.17	6.71	52.13
I	4.25	at birth	0.08	0.23	4.07	59.65	7.52	62.39
S	4.84	at birth	0.32	1.48	4.57	63.18	8.00	45.60
<i>pooled</i>	<i>3.24</i>	<i>-0.13*</i>	<i>0.10</i>	<i>0.43</i>	<i>2.70</i>	<i>74.80</i>	<i>4.18</i>	<i>56.21</i>

Figure 4 Age (in years) at diagnosis








Boxplots: cross represents median, box represents 25th to 75th percentiles, whiskers represent minimum and maximum.

Figure 5 Frequencies (%) of neonates positive at screening and neonates positive at meconium ileus



Data not available for Germany; 3.63% of missing data for France.

Figure 6 Genotype: frequencies (%) of F508del mutation



%

The category "other" includes unknown mutations (i.e. remained unidentified after testing).
The category "missing" includes patients not undergone DNA testing.

Figure 7 Allelic frequencies (%) of unknown mutations





Figure 8 Frequencies (%) of deceased patients in one year (95% C.I.)



Austria, Israel and Sweden: no deaths reported during year 2006.

Table 4.1 Lung transplantation: frequencies (%)

country	transplantation performed		
	don't know	never	yes
A	-	106 (99.07)	1 (0.93)
B	954 (92.08)	6 (0.58)	76 (7.34)
CZ	457 (100.00)	-	-
DK	-	397 (90.64)	41 (9.36)
D	-	4810 (98.28)	84 (1.72)
F	-	4768 (95.47)	226 (4.52)
IRL	832 (100.00)	-	-
IL	-	433 (96.87)	14 (3.13)
I	-	738 (95.72)	33 (4.28)
S	-	125 (100.00)	-
<i>total</i>	<i>3001</i> <i>(21.28)</i>	<i>10625</i> <i>(72.35)</i>	<i>475</i> <i>(3.37)</i>

Table 4.2 Year of lung transplantation: frequencies (%)

country	transplantation performed			
	before this year	during this year	before and during this year	year unknown
A	1 (0.93)	-	-	-
B	64 (6.18)	12 (1.16)	-	-
CZ	-	-	-	-
DK	27 (6.16)	14 (3.20)	-	-
D	61 (1.25)	18 (0.37)	-	5 (0.10)
F	171 (3.42)	55 (1.10)	-	-
IRL	-	-	-	-
IL	9 (2.01)	5 (1.12)	-	-
I	24 (3.11)	8 (1.04)	1 (0.13)	-
S	-	-	-	-
<i>total</i>	<i>357 (2.53)</i>	<i>112 (0.79)</i>	<i>1 (0.01)</i>	<i>5 (0.04)</i>


Table 5.1 Liver transplantation: frequencies (%)

country	transplantation performed		
	don't know	never	yes
A	-	103 (96.26)	4 (3.74)
B	954 (92.08)	74 (7.14)	8 (0.78)
CZ	457 (100.00)	-	-
DK	-	435 (99.32)	3 (0.68)
D	-	4880 (99.71)	14 (0.29)
F	-	4976 (94.64)	18 (0.36)
IRL	832 (100.00)	-	-
IL	447 (100.00)	-	-
I	-	769 (99.74)	2 (0.26)
S	-	124 (99.20)	1 (0.80)
<i>total</i>	<i>2690 (19.08)</i>	<i>11361 (80.57)</i>	<i>50 (0.35)</i>

Table 5.2 Year of liver transplantation: frequencies (%)


country	transplantation performed		
	before this year	during this year	year unknown
A	4 (3.74)	-	-
B	7 (0.68)	1 (0.10)	-
CZ	-	-	-
DK	3 (0.68)	-	-
D	10 (0.20)	3 (0.06)	1 (0.02)
F	13 (0.26)	5 (0.10)	-
IRL	-	-	-
IL	-	-	-
I	1 (0.13)	1 (0.13)	-
S	-	1 (0.80)	-
<i>total</i>	<i>38 (0.27)</i>	<i>11 (0.08)</i>	<i>1 (0.01)</i>

Figure 9.1 Frequencies (%) of chronic *Pseudomonas aeruginosa* and chronic *Burkholderia cepacia* infections



Pseudomonas aeruginosa infection: data not available for Czech Republic and Ireland; due to high proportion of missing data (27.80%) estimates for Belgium are unreliable.
Burkholderia cepacia infection: data not available for Belgium, Czech Republic and Ireland.


Figure 9.2 Frequencies (%) of chronic *Pseudomonas aeruginosa* and chronic *Burkholderia cepacia* infections (<18 years)



Pseudomonas aeruginosa infection: data not available for Czech Republic and Ireland; due to high proportion of missing data (32.83%) estimates for Belgium are unreliable.

Burkholderia cepacia infection: data not available for Belgium, Czech Republic and Ireland.


Figure 9.3 Frequencies (%) of chronic *Pseudomonas aeruginosa* and chronic *Burkholderia cepacia* infections (≥ 18 years)




Pseudomonas aeruginosa infection: data not available for Czech Republic and Ireland; due to high proportion of missing data (22.13%) estimates for Belgium are unreliable.

Burkholderia cepacia infection: data not available for Belgium, Czech Republic and Ireland.

Figure 10 FEV1* (%predicted) quartiles, by age





For groups with n<10, 25th and 75th percentiles were not calculated.

*transplanted patients were excluded from the analysis


FEV1% of predicted was calculated with a common set of reference equations:

for male children (6-17 yrs) and female children (6-15 yrs): Wang *et al*¹



for male adults (≥ 18 yrs) and female adults (≥ 16 yrs): Hankinson *et al*².

For children (< 6 yrs) no calculation of percentage of predicted values was performed because of lack of valid reference equations.



Figure 11 Quartiles of z-scores for height and weight





France



Germany





Israel





age

Italy



Sweden




age

75th percentile
 median
 25th percentile



For groups with n<10, 25th and 75th percentiles were not calculated.

International references³ were used to calculate z-score.



Figure 12 Quartiles of z-scores for height and weight, by gender (pink=females, blue=males)





France



Germany





Israel





age

Italy



Sweden



age

75th percentile
 median
 25th percentile

For groups with n<10, 25th and 75th percentiles were not calculated.

International references³ were used to calculate z-score.

¹ Wang X, Dockery DW, Wypij D, Fay ME, Ferris BG. Pulmonary function between 6 and 18 years of age. *Pediatr Pulmonol* 1993;15:75-88.

² Hankinson JL, Odencrantz RJ, Fedan KB. Spirometric reference values from a sample of the general U.S. population. *Am J Respr Crit Care Med* 1999;159:179-87.

³ Kuczmarski RJ, Ogden CL, Guo SS et al. 2000 CDC growth charts for the United States: Methods and development. *National Center for Health Statistics. Vital Health Stat* 2002;11(246):1-190.